Skip to content
PubMed This is a summary of 79 peer-reviewed journal articles Updated
Pulmonology

Non-Specific Interstitial Pneumonia (NSIP): A Patient Guide

At a Glance

NSIP is a pattern of inflammation and scarring in the lungs, not a single disease with one cause. Doctors use imaging, biopsy when needed, and evaluation for autoimmune conditions to guide individualized treatment and long-term monitoring.

Non-Specific Interstitial Pneumonia (NSIP) is a rare and complex lung condition characterized by a specific pattern of inflammation and scarring within the deep tissues of the lungs. Unlike many diseases that are defined by a single cause, NSIP is often a “pattern of injury” that the lungs develop in response to various triggers, such as an underlying autoimmune disorder, certain medications, or environmental exposures [1]. Because this pattern can look like several other types of lung disease, reaching a definitive diagnosis often benefits from a multidisciplinary approach, where lung specialists, radiologists, and pathologists work together to review the evidence [2].

What NSIP Does Not Mean

Having an “NSIP pattern” on a scan or biopsy does not automatically determine your prognosis, severity, or exact treatment. A working diagnosis can evolve as new information—such as the emergence of an autoimmune disease—becomes available.

Understanding your specific type of NSIP is an important step in managing the condition, as it typically presents in two broad forms: cellular and fibrotic. The cellular form is dominated by inflammation and often responds to immunosuppressive treatment, while the fibrotic form involves more permanent scarring [3]. However, these are broad concepts, and many patients have “mixed” disease with overlapping features. Distinguishing between these forms—and ruling out look-alike conditions like Idiopathic Pulmonary Fibrosis (IPF)—is critical because the treatments can vary significantly [4]. Identifying whether your NSIP is “secondary” to another condition, like lupus or rheumatoid arthritis, is also a priority, as treating the primary cause is often the best way to protect your lungs [5].

Living with NSIP is a long-term journey that involves balancing medical treatment with daily wellness. Treatment plans are highly individualized, often focusing on “quieting” an overactive immune system or, in selected progressive fibrosing cases, using medications that specifically target scar tissue formation [6]. Alongside these medications, your care will likely include regular breathing tests to track your progress and pulmonary rehabilitation to help you stay active and strong [7]. While a diagnosis of a rare lung disease comes with uncertainty, consistent monitoring and a personalized management plan can help you navigate the challenges of the condition.

Common questions in this guide

What is NSIP, and what can cause it?
NSIP is a pattern of inflammation and scarring in the lung tissue rather than a condition with one universal cause. It can be associated with autoimmune or connective tissue diseases, certain medications, or environmental exposures, so clinicians may continue looking for an underlying cause.
How are cellular and fibrotic NSIP different?
Cellular NSIP has more inflammation and may respond to medicines that suppress overactive immune activity. Fibrotic NSIP has more established scarring, and some people have mixed features, so treatment depends on the full clinical, imaging, and biopsy picture.
How do doctors confirm an NSIP diagnosis?
A multidisciplinary team may review your medical history, imaging, and biopsy findings when available. A lung specialist, radiologist, and pathologist may work together to distinguish NSIP from other interstitial lung diseases, including idiopathic pulmonary fibrosis, and the working diagnosis can change if new information appears.
What treatments may be used for NSIP?
Treatment is individualized and may include treating an underlying autoimmune condition, medicines that calm an overactive immune response, or medicines that target scar formation in selected progressive fibrosing cases. Pulmonary rehabilitation and regular breathing tests may support physical activity and help track changes over time.
How is NSIP monitored over time?
Care may include regular breathing tests to follow lung function and monitoring of symptoms and ability to stay active. Pulmonary rehabilitation can help maintain strength and activity, while the medication plan may change as the disease pattern or an underlying cause becomes clearer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tests, do I have the cellular or fibrotic form of NSIP, and what does that mean for my treatment path?
  2. 2.How certain is the multidisciplinary team about this diagnosis compared to other interstitial lung diseases?
  3. 3.Are we continuing to look for an underlying cause, such as an autoimmune or connective tissue disease?
  4. 4.What are the long-term goals for my lung function and physical activity?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (7)
  1. 1

    Idiopathic non-specific interstitial pneumonia.

    Belloli EA, Beckford R, Hadley R, Flaherty KR

    Respirology (Carlton, Vic.) 2016; (21(2)):259-68 doi:10.1111/resp.12674.

    PMID: 26564810
  2. 2

    Imaging Features of Idiopathic Interstitial Lung Diseases.

    Batra K, Adams TN

    Journal of thoracic imaging 2023; (38(Suppl 1)):S19-S29 doi:10.1097/RTI.0000000000000728.

    PMID: 37505195
  3. 3

    Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management?

    Tomassetti S, Ryu JH, Piciucchi S, et al.

    Seminars in respiratory and critical care medicine 2016; (37(3)):378-94 doi:10.1055/s-0036-1583176.

    PMID: 27231862
  4. 4

    Pathology of Chronic Hypersensitivity Pneumonitis What Is It? What Are the Diagnostic Criteria? Why Do We Care?

    Churg A, Bilawich A, Wright JL

    Archives of pathology & laboratory medicine 2018; (142(1)):109-119 doi:10.5858/arpa.2017-0173-RA.

    PMID: 28537805
  5. 5

    High-Resolution CT Findings in Interstitial Lung Disease Associated with Connective Tissue Diseases: Differentiating Patterns for Clinical Practice-A Systematic Review with Meta-Analysis.

    Drimus JC, Duma RC, Trăilă D, et al.

    Journal of clinical medicine 2025; (14(17)) doi:10.3390/jcm14176164.

    PMID: 40943925
  6. 6

    Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.

    Raghu G, Montesi SB, Silver RM, et al.

    American journal of respiratory and critical care medicine 2024; (209(2)):137-152 doi:10.1164/rccm.202306-1113ST.

    PMID: 37772985
  7. 7

    Functional, radiological and survival outcomes in rheumatoid arthritis-associated interstitial lung disease: 24-month results from the BERTHA prospective cohort.

    Kawano-Dourado L, Bonfiglioli K, Ribeiro ACM, et al.

    BMJ open respiratory research 2026; (13(1)) doi:10.1136/bmjresp-2025-003973.

    PMID: 41760357

This page about NSIP is for informational purposes only and does not constitute medical advice. Your pulmonologist and multidisciplinary care team should interpret your results and guide treatment for your situation.

Get notified when new evidence is published on Non-specific interstitial pneumonia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.